Filtrar por género

Dr. John Campbell

Dr. John Campbell

Campbellteaching

Hello Everyone, My name is John Campbell and I am a retired Nurse Teacher and former clinical nurse based in England. I also do some teaching in Asia and Africa when time permits. These videos are to help students to learn the background to all forms of health care. My PhD focused on the development of open learning resources for nurses nationally and internationally. LinkedIn profile, https://www.linkedin.com/in/dr-john-campbell-5256223b/ Twitter, https://twitter.com/Johnincarlisle Disclaimer; These media including videos, book, e book, articles, podcasts are not peer-reviewed. They should never replace individual clinical judgement from your own health care provider. No media-based material on this channel is suitable for using as professional medical advice. All comments are also for educational purposed only and must never replace advice from your own health care provider

1029 - Your cancer feedback
0:00 / 0:00
1x
  • 1029 - Your cancer feedback

    Free download for books and posters, https://drjohncampbell.co.uk/ Hard new copy of the Physiology notes if you live in the UK, https://www.ebay.co.uk/p/86647350 Learn more about your ad choices. Visit megaphone.fm/adchoices

    Mon, 21 Sep 2026
  • 1028 - Paxlovid, evidence base?

    Paxlovid, it this an evidence based intervention in May 2022? Paper FDA EMU was based on https://www.nejm.org/doi/full/10.1056/NEJMoa2118542 EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients) 1120 patients received nirmatrelvir plus ritonavir 1126 received placebo Relative risk reduction Risk of progression to severe Covid-19, 89% lower than the risk with placebo Absolute risk reduction https://www.precisionvaccinations.com/what-paxlovids-absolute-and-relative-covid-19-risk-reduction 7% down to 1% symptomatic, unvaccinated, non hospitalized adults at high risk for progression to severe coronavirus disease 2019 July 16 and December 9, 2021 If vaccinated people and previously infected people are partly protected More people would need to be treated to prevent one adverse event Pfizer press release (5th November 2021) https://www.pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate our oral antiviral candidate, … has the potential to save patients’ lives, reduce the severity of COVID-19 infections, and eliminate up to nine out of ten hospitalizations Pfizer Shares In Vitro Efficacy of Novel COVID-19 Oral Treatment Against Omicron Variant https://www.pfizer.com/news/press-release/press-release-detail/pfizer-shares-vitro-efficacy-novel-covid-19-oral-treatment https://www.yalemedicine.org/news/12-things-to-know-paxlovid-covid-19 https://www.fda.gov/media/155051/download The results showed in all cases that nirmatrelvir was a potent inhibitor of its target. PAXLOVID™ for Post-Exposure Prophylactic Use https://www.pfizer.com/news/press-release/press-release-detail/pfizer-shares-top-line-results-phase-23-epic-pep-study Evaluated data from 2,957 adults Pfizer observed risk reductions of 32% (5 day course) 37% reduction (10 day course) These results, however, were not statistically significant and, as such, the primary endpoint of reducing the risk of confirmed and symptomatic COVID-19 infection in adults who had been exposed to the virus through a household contact was not met. FACT SHEET FOR PATIENTS, PARENTS, AND CAREGIVERS EMERGENCY USE AUTHORIZATION (EUA) OF PAXLOVID FOR CORONAVIRUS DISEASE 2019 (COVID-19) https://www.fda.gov/media/155051/download PAXLOVID is not an FDA-approved medicine in the United States. PAXLOVID is an investigational medicine Some medicines may interact with PAXLOVID and may cause serious side effects. If you take too much PAXLOVID, call your healthcare provider or go to the nearest hospital emergency room right away. Possible side effects of PAXLOVID are: Allergic Reactions trouble swallowing or breathing, swelling of the mouth, lips, or face, throat tightness, hoarseness, skin rash Liver Problems. Tell your healthcare provider right away, loss of appetite, yellowing of your skin and the whites of eyes (jaundice), dark-colored urine, pale colored stools and itchy skin, stomach area (abdominal) pain. Other possible side effects include: altered sense of taste, diarrhea, high blood pressure, muscle aches Dr. Ashish K. Jha, White House, Covid-19 coordinator The new White House Covid czar says avoiding all virus infections isn’t the goal of U.S. pandemic policy. Paxlovid, push to reach the vulnerable Doctors are too hesitant to prescribe the drug https://en.wikipedia.org/wiki/Ashish_Jha Senior Advisor at Albright Stonebridge Group https://www.politico.com/newsletters/transition-playbook/2021/03/23/the-blob-abides-492214 The firm advises clients on international policy and global markets Patrick Vallance From 2012 to 2018, he was President of Research and Development at global pharmaceutical company, GlaxoSmithKline (GSK) https://www.telegraph.co.uk/news/2020/09/23/revealed-sir-patrick-vallance-has-600000-shareholding-firm-contracted/ Cashed £5,000,000 GSK share Learn more about your ad choices. Visit megaphone.fm/adchoices

    Mon, 21 Sep 2026
  • 1027 - Menstruation changes

    Unexpected vaginal bleeding and COVID-19 vaccination in nonmenstruating women https://pubmed.ncbi.nlm.nih.gov/37738335/ Altered bleeding pattern after COVID-19 vaccination has been frequently addressed among menstruating women Menstrual abnormalities after COVID-19 vaccines: A systematic review https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9294036/ A total of 78, 138 vaccinated women (14 studies). 39, 759 (52.05%) had some form of a menstrual problem after vaccination. 22nd September 2023 The Norwegian Institute of Public Health Association between COVID-19 vaccination and vaginal bleeding, among nonmenstruating women is not well studied. Menorrhagia, increased bleeding during period Metrorrhagia, Irregular bleeds / between menstrual periods. Polymenorrhea, less than 21 day cycles, therefore more frequent periods Several cohorts followed throughout the pandemic Systematic data collection of self-reporting. Percentages of unexpected vaginal bleeding (During a period of 8 to 9 months) 50% happened within 28 days of vaccination. 7,725 postmenopausal women, 3.3% 7,148 perimenopausal women, 14.1% 7,052 premenopausal women, 13.1% In postmenopausal women The risk of unexpected vaginal bleeding, in the 4 weeks after vaccination, was increased two to threefold, compared to a prevaccination period. https://openpublichealthjournal.com/VOLUME/16/ELOCATOR/e187494452305083/FULLTEXT/ 11.1% and 37.5% experienced menstrual symptoms In nonmenstruating perimenopausal and premenopausal women Risk of unexpected (breakthrough) vaginal bleeding after vaccination Increased three to fivefold In premenopausal women Spikevax was associated with at 32% increased risk as compared to Comirnaty. More detail Reports since December 2020, menstrual disturbances at frequencies not seen in previous vaccination campaigns Such events were not addressed in the preceding clinical vaccine trials European Medicines Agency Recently updated product information of the mRNA vaccines, to include heavy menstrual bleeding as a potential side effect. PMB can be a symptom of endometrial carcinoma and precancerous lesions Women with PMB should be referred for specialized gynecological examination Learn more about your ad choices. Visit megaphone.fm/adchoices

    Mon, 21 Sep 2026
  • 1026 - More DNA contamination now allowed

    DNA contamination clearly identified by Dr David Speicher An Injection of Truth. Healing Humanity. https://aninjectionoftruth.ca/ The David Declaration https://thedaviddeclaration.org/ Learn more about your ad choices. Visit megaphone.fm/adchoices

    Sun, 20 Sep 2026
  • 1025 - 15 million excess deaths

    Official reported deaths https://covid19.who.int Cases, 513,384,685 Deaths, 6,246,828 Technical Advisory Group on COVID-19 Mortality Assessment https://www.who.int/data/technical-advisory-group/covid-19--mortality-assessment/membership Five working groups e.g. group one https://www.who.int/data/technical-advisory-group/covid-19--mortality-assessment/working-group-1 Convened jointly by the WHO and the United Nations Department of Economic and Social Affairs (UN DESA) Methods used https://www.who.int/publications/m/item/methods-for-estimating-the-excess-mortality-associatedwith-the-covid-19-pandemic https://cdn.who.int/media/docs/default-source/world-health-data-platform/covid-19-excessmortality/who_methods_for_estimating_the_excess_mortality_associated_with_the_covid-19_pandemic.pdf?sfvrsn=5a05fa76_1&download=true 14.9 million excess deaths associated with the COVID-19 pandemic in 2020 and 2021 https://www.who.int/news/item/05-05-2022-14.9-million-excess-deaths-were-associated-with-the-covid-19-pandemic-in-2020-and-2021 Full death toll associated directly or indirectly with the pandemic That is, excess mortality 1 January 2020 and 31 December 2021 Range 13.3 million to 16.6 million Dr Tedros Adhanom Ghebreyesus, WHO Director-General These sobering data not only point to the impact of the pandemic but also to the need for all countries to invest in more resilient health systems that can sustain essential health services during crises, including stronger health information systems Generate better data for better decisions and better outcomes Excess mortality Number of deaths that have occurred and the number expected (in the absence of the pandemic) Direct and indirect deaths (due to the pandemic’s impact on health systems and society) Health care systems overburdened Deaths averted during the pandemic Motor-vehicle accidents, occupational injuries Most of the excess deaths (84%) South-East Asia, Europe, the Americas High-income and low-income countries, 15% of total 14.9 m Low income countries, 4% of total 14.9 m Sex Male, 57% of total 14.9 m Female, 43% of total 14.9 m Dr Samira Asma, Assistant Director-General for Data, Analytics and Delivery, WHO Measurement of excess mortality is an essential component to understand the impact of the pandemic. Shifts in mortality trends provide decision-makers information to guide policies to reduce mortality and effectively prevent future crises. Because of limited investments in data systems in many countries, the true extent of excess mortality often remains hidden These new estimates use the best available data and have been produced using a robust methodology and a completely transparent approach Dr Ibrahima Socé Fall, Assistant Director-General for Emergency Response Data is the foundation of our work every day to promote health, keep the world safe, and serve the vulnerable. Need to track outbreaks in real-time, everywhere We know where the data gaps are Mr Liu Zhenmin, United Nations Under-Secretary-General for Economic and Social Affairs The United Nations system is working together to deliver an authoritative assessment of the global toll of lives lost from the pandemic. This work is an important part of UN DESA’s ongoing collaboration with WHO and other partners to improve global mortality estimates Mr Stefan Schweinfest, Director of the Statistics Division of UN DESA Data deficiencies make it difficult to assess the true scope of a crisis, with serious consequences for people’s lives. The pandemic has been a stark reminder of the need for better coordination of data systems within countries and for increased international support for building better systems, including for the registration of deaths and other vital events. Learn more about your ad choices. Visit megaphone.fm/adchoices

    Sun, 20 Sep 2026
Mostrar más episodios